These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25027670)

  • 1. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
    Choudhury A; Arthur C; Malik J; Mandall P; Taylor C; Alam N; Tran A; Livsey J; Elliott T; Davidson S; Logue JP; Wylie J
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):661-7. PubMed ID: 25027670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
    Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
    Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
    Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
    Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer.
    Den RB; Greenspan J; Doyle LA; Harrison AS; Peng C; Williams NL; Lallas CD; Trabulsi EJ; Gomella LG; Hurwitz MD; Leiby B; Dicker AP
    Brachytherapy; 2020; 19(3):282-289. PubMed ID: 32217038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the changes in the EPIC QOL scores and the dose-volume histogram parameters in high-dose-rate brachytherapy combined with hypofractionated external beam radiation therapy for prostate cancer.
    Hashimoto Y; Akimoto T; Iizuka J; Tanabe K; Mitsuhashi N
    Jpn J Clin Oncol; 2015 Jan; 45(1):81-7. PubMed ID: 25425700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
    Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
    Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
    Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
    Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
    Crook J; Moideen N; Arbour G; Castro F; Araujo C; Batchelar D; Halperin R; Hilts M; Kim D; Petrik D; Rose J; Cheng JC; Bachand F
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):59-68. PubMed ID: 38493901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
    Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
    Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
    Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
    Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.